SCHEMBL5947635

SCHEMBL5947635

CCOC(=O)c1ccc2[nH]cc(CCNCc3cccc(OCC(F)(F)F)c3)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 5/20 0.52
▸ HTR1A P08908 1/20 0.52
▸ DRD2 P14416 1/20 0.52
▸ HTR2C P28335 1/20 0.52
▸ HTR7 P34969 1/20 0.52
▸ HTR6 P50406 1/20 0.52
▸ KMT2A Q03164 2/20 0.50
▸ TRPM8 Q7Z2W7 1/20 0.49
▸ ACHE P22303 3/20 0.48
▸ BCHE P06276 2/20 0.48
▸ TRPV1 Q8NER1 3/20 0.46
▸ LTA4H P09960 2/20 0.46
▸ PLA2G2A P14555 2/20 0.46
▸ SNCA P37840 2/20 0.44
▸ HDAC3 O15379 1/20 0.44
▸ HDAC4 P56524 1/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC7 Q8WUI4 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC10 Q969S8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947388 0.93 HTR6 (0.58) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL2533028 0.92 KMT2A (0.55) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL5947226 0.92 HTR2A (0.64) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL2532835 0.89 HTR2A (0.56) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL5947442 0.86 LTA4H (0.57) HTR2AKMT2ATRPM8ACHEBCHE
SCHEMBL5947844 0.86 HTR2A (0.58) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL5947509 0.85 HTR6 (0.71) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL5947754 0.85 HTR6 (0.61) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL5947731 0.85 HTR2A (0.63) HTR2AHTR1ADRD2HTR2CHTR7
SCHEMBL5947626 0.84 HTR2A (0.60) HTR2AHTR1ADRD2HTR2CHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B HTR2A 5/4885HTR1A 6/4885DRD2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback